Posted On: 11/19/2013 12:15:05 PM
Post# of 36728
re- Epilepsy. Important new British study findings released. Add "cannabidivarin" (CBDV) to the discussion vocabulary. Appears to support BB's all-natural "whole-plant" model of healing. Another point of interest is CBDV not mediated by CB1 cannabinoid receptor .
Findings: "CBDV (Cannabidivarin) BDSs (botanical drug substances) exerted significant anticonvulsant effects in three models of seizure that were not mediated by the CB1 cannabinoid receptor and were of comparable efficacy with purified CBDV. These findings strongly support the further clinical development of CBDV BDSs for the treatment of epilepsy."
("Cannabidivarin (CBDV) is a non-psychoactive cannabinoid found in Cannabis. It is a homologue of cannabidiol (CBD), with the side-chain shortened by two methylene bridges (CH2 units). Plants with relatively high levels of CBDV have been reported in feral populations of C. indica ( = C. sativa ssp. indica var. kafiristanica) from northwest India, and in hashish from Nepal. Similarly to CBD, it has 7 double bond isomers and 30 stereoisomers. It is not scheduled by Convention on Psychotropic Substances.")
British Journal of Pharmacology. 2013 Oct;170(3):679-92. doi: 10.1111/bph.12321.
Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism.
Hill TD, Cascio MG, Romano B, Duncan M, Pertwee RG, Williams CM, Whalley BJ, Hill AJ.
Reading School of Pharmacy, University of Reading, Reading, UK.
Abstract
BACKGROUND AND PURPOSE: Epilepsy is the most prevalent neurological disease and is characterized by recurrent seizures. Here, we investigate (i) the anticonvulsant profiles of cannabis-derived botanical drug substances (BDSs) rich in cannabidivarin (CBDV) and containing cannabidiol (CBD) in acute in vivo seizure models and (ii) the binding of CBDV BDSs and their components at cannabinoid CB1 receptors.
EXPERIMENTAL APPROACH: The anticonvulsant profiles of two CBDV BDSs (50-422?mg·kg(-1) ) were evaluated in three animal models of acute seizure. Purified CBDV and CBD were also evaluated in an isobolographic study to evaluate potential pharmacological interactions. CBDV BDS effects on motor function were also investigated using static beam and grip strength assays. Binding of CBDV BDSs to cannabinoid CB1 receptors was evaluated using displacement binding assays.
KEY RESULTS : CBDV BDSs exerted significant anticonvulsant effects in the pentylenetetrazole (?100?mg·kg(-1) ) and audiogenic seizure models (?87?mg·kg(-1) ), and suppressed pilocarpine-induced convulsions (?100?mg·kg(-1) ). The isobolographic study revealed that the anticonvulsant effects of purified CBDV and CBD were linearly additive when co-administered. Some motor effects of CBDV BDSs were observed on static beam performance; no effects on grip strength were found. The Delta(9) -tetrahydrocannabinol and Delta(9) -tetrahydrocannabivarin content of CBDV BDS accounted for its greater affinity for CB1 cannabinoid receptors than purified CBDV.
CONCLUSIONS AND IMPLICATIONS : CBDV BDSs exerted significant anticonvulsant effects in three models of seizure that were not mediated by the CB1 cannabinoid receptor and were of comparable efficacy with purified CBDV. These findings strongly support the further clinical development of CBDV BDSs for the treatment of epilepsy.
http://www.ncbi.nlm.nih.gov/pubmed/23902406
Findings: "CBDV (Cannabidivarin) BDSs (botanical drug substances) exerted significant anticonvulsant effects in three models of seizure that were not mediated by the CB1 cannabinoid receptor and were of comparable efficacy with purified CBDV. These findings strongly support the further clinical development of CBDV BDSs for the treatment of epilepsy."
("Cannabidivarin (CBDV) is a non-psychoactive cannabinoid found in Cannabis. It is a homologue of cannabidiol (CBD), with the side-chain shortened by two methylene bridges (CH2 units). Plants with relatively high levels of CBDV have been reported in feral populations of C. indica ( = C. sativa ssp. indica var. kafiristanica) from northwest India, and in hashish from Nepal. Similarly to CBD, it has 7 double bond isomers and 30 stereoisomers. It is not scheduled by Convention on Psychotropic Substances.")
British Journal of Pharmacology. 2013 Oct;170(3):679-92. doi: 10.1111/bph.12321.
Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism.
Hill TD, Cascio MG, Romano B, Duncan M, Pertwee RG, Williams CM, Whalley BJ, Hill AJ.
Reading School of Pharmacy, University of Reading, Reading, UK.
Abstract
BACKGROUND AND PURPOSE: Epilepsy is the most prevalent neurological disease and is characterized by recurrent seizures. Here, we investigate (i) the anticonvulsant profiles of cannabis-derived botanical drug substances (BDSs) rich in cannabidivarin (CBDV) and containing cannabidiol (CBD) in acute in vivo seizure models and (ii) the binding of CBDV BDSs and their components at cannabinoid CB1 receptors.
EXPERIMENTAL APPROACH: The anticonvulsant profiles of two CBDV BDSs (50-422?mg·kg(-1) ) were evaluated in three animal models of acute seizure. Purified CBDV and CBD were also evaluated in an isobolographic study to evaluate potential pharmacological interactions. CBDV BDS effects on motor function were also investigated using static beam and grip strength assays. Binding of CBDV BDSs to cannabinoid CB1 receptors was evaluated using displacement binding assays.
KEY RESULTS : CBDV BDSs exerted significant anticonvulsant effects in the pentylenetetrazole (?100?mg·kg(-1) ) and audiogenic seizure models (?87?mg·kg(-1) ), and suppressed pilocarpine-induced convulsions (?100?mg·kg(-1) ). The isobolographic study revealed that the anticonvulsant effects of purified CBDV and CBD were linearly additive when co-administered. Some motor effects of CBDV BDSs were observed on static beam performance; no effects on grip strength were found. The Delta(9) -tetrahydrocannabinol and Delta(9) -tetrahydrocannabivarin content of CBDV BDS accounted for its greater affinity for CB1 cannabinoid receptors than purified CBDV.
CONCLUSIONS AND IMPLICATIONS : CBDV BDSs exerted significant anticonvulsant effects in three models of seizure that were not mediated by the CB1 cannabinoid receptor and were of comparable efficacy with purified CBDV. These findings strongly support the further clinical development of CBDV BDSs for the treatment of epilepsy.
http://www.ncbi.nlm.nih.gov/pubmed/23902406
(0)
(0)Scroll down for more posts ▼
